James Hardwick
James Hardwick
Affiliation inconnue
Aucune adresse e-mail validée
Citée par
Citée par
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
R Cristescu, J Lee, M Nebozhyn, KM Kim, JC Ting, SS Wong, J Liu, ...
Nature medicine 21 (5), 449-456, 2015
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma
WK Sung, H Zheng, S Li, R Chen, X Liu, Y Li, NP Lee, WH Lee, ...
Nature genetics 44 (7), 765-769, 2012
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors
J O'Neil, J Grim, P Strack, S Rao, D Tibbitts, C Winter, J Hardwick, ...
The Journal of experimental medicine 204 (8), 1813-1824, 2007
Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins
JS Hardwick, FG Kuruvilla, JK Tong, AF Shamji, SL Schreiber
Proceedings of the National Academy of Sciences 96 (26), 14866-14870, 1999
Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12–rapamycinassociated protein
RT Peterson, BN Desai, JS Hardwick, SL Schreiber
Proceedings of the National Academy of Sciences 96 (8), 4438-4442, 1999
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
G Garcia-Manero, H Yang, C Bueso-Ramos, A Ferrajoli, J Cortes, ...
Blood, The Journal of the American Society of Hematology 111 (3), 1060-1066, 2008
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Z Kan, H Zheng, X Liu, S Li, TD Barber, Z Gong, H Gao, K Hao, ...
Genome research 23 (9), 1422-1433, 2013
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study
E Galanis, KA Jaeckle, MJ Maurer, JM Reid, MM Ames, JS Hardwick, ...
Journal of clinical oncology 27 (12), 2052, 2009
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized …
BL Rapoport, K Jordan, JA Boice, A Taylor, C Brown, JS Hardwick, ...
Supportive Care in Cancer 18 (4), 423-431, 2010
Activation of the Lck tyrosine protein kinase by hydrogen peroxide requires the phosphorylation of Tyr-394
JS Hardwick, BM Sefton
Proceedings of the National Academy of Sciences 92 (10), 4527-4531, 1995
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE
S Grunberg, D Chua, A Maru, J Dinis, S DeVandry, JA Boice, JS Hardwick, ...
Journal of Clinical Oncology 29 (11), 1495-1501, 2011
Development of vorinostat: current applications and future perspectives for cancer therapy
VM Richon, J Garcia-Vargas, JS Hardwick
Cancer letters 280 (2), 201-210, 2009
Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers
A Saadi, NB Shannon, P Lao-Sirieix, M O’Donovan, E Walker, ...
Proceedings of the National Academy of Sciences 107 (5), 2177-2182, 2010
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer
JF Gainor, D Tseng, S Yoda, I Dagogo-Jack, L Friboulet, JJ Lin, ...
JCO precision oncology 1, 1-13, 2017
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells
SS Rao, J O'Neil, CD Liberator, JS Hardwick, X Dai, T Zhang, E Tyminski, ...
Cancer research 69 (7), 3060-3068, 2009
A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia
CJ Peters, JRE Rees, RH Hardwick, JS Hardwick, SL Vowler, CAJ Ong, ...
Gastroenterology 139 (6), 1995-2004. e15, 2010
Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing
SS Wong, KM Kim, JC Ting, K Yu, J Fu, S Liu, R Cristescu, M Nebozhyn, ...
Nature communications 5 (1), 1-12, 2014
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid …
F Atzori, J Tabernero, A Cervantes, L Prudkin, J Andreu, ...
Clinical Cancer Research 17 (19), 6304-6312, 2011
The activated form of the Lck tyrosine protein kinase in cells exposed to hydrogen peroxide is phosphorylated at both Tyr-394 and Tyr-505
JS Hardwick, BM Sefton
Journal of Biological Chemistry 272 (41), 25429-25432, 1997
Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma
KG Paulson, A Tegeder, C Willmes, JG Iyer, OK Afanasiev, D Schrama, ...
Cancer immunology research 2 (11), 1071-1079, 2014
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20